Elite in Down Syndrome

Andre M. Strydom

16 De Crespigny Park, 
London, ENG, GB 
Elite in Down Syndrome
16 De Crespigny Park, 
London, ENG, GB 
OverviewLocationsClinical Research

Overview

Andre Strydom practices in London, United Kingdom. Mr. Strydom is rated as an Elite expert by MediFind in the treatment of Down Syndrome. His top areas of expertise are Down Syndrome, Dementia, Alzheimer's Disease, and Developmental Dysphasia Familial.

His clinical research consists of co-authoring 174 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 84 articles and participated in 1 clinical trial in the study of Down Syndrome.

Gender
Male

Locations

16 De Crespigny Park, London, ENG, United Kingdom
Other Locations
147 Tottenham Court Road, London, ENG, United Kingdom
2nd Floor Charles Bell House, 67-73 Riding House Street, W1W 7EY, London, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Elucidating Age-related Comorbidity Patterns in Down Syndrome (DS): Prospective Cohort (GO-DS21 Cohort Study)
Elucidating Age-related Comorbidity Patterns in Down Syndrome (DS): Prospective Cohort (GO-DS21 Cohort Study)
Enrollment Status: Completed
Publish Date: July 09, 2025
Intervention Type: Other
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT
Enrollment Status: Active_not_recruiting
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: ZYN002
Study Phase: Phase 3
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders
A Phase II Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Arbaclofen Administered for the Treatment of Social Function in Children and Adolescents With Autism Spectrum Disorders
Enrollment Status: Completed
Publish Date: February 08, 2023
Intervention Type: Drug
Study Drug: Arbaclofen
Study Phase: Phase 2
View 2 Less Clinical Trials

168 Total Publications

Investigating the use and impact of community Care (Education) and Treatment Reviews (C(E)TRs) in people with intellectual disability and autistic people: protocol for a cohort study using electronic health records.
Investigating the use and impact of community Care (Education) and Treatment Reviews (C(E)TRs) in people with intellectual disability and autistic people: protocol for a cohort study using electronic health records.
Journal: BMJ open
Published: October 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Strydom's expertise for a condition
ConditionClose
View All 14 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile